7 results about "GSTP1" patented technology

The invention relates to application of a GSTP1 inhibitor in preparation of a medicine for treating chronic myelogenous leukemia, and belongs to the technical field of biomedicine. According to the application, it is found for the first time that interaction exists between CML core driving proteins BCR-ABL1 and GSTP1, GSTP1-mediated BCR-ABL1 protein glutathione modification can be effectively inhibited through targeted inhibition of the expression level of the GSTP1, the stability of the BCR-ABL1 protein is reduced, CML cell proliferation is inhibited, and CML cell apoptosis is promoted, so that the effect of treating the chronic myeloid leukemia is achieved. Therefore, the GSTP1 can be used as a treatment target, the GSTP1 inhibitor Ezatiostat is used for preparing the medicine for treating the chronic myelogenous leukemia, a theoretical basis and possibility are provided for developing a GSTP1 inhibitor and TKI combined medication scheme in the future, synergistic interaction is expected, and prognosis of a patient is further improved.

Disclosed are pathogenic mechanisms in pulmonary hypertension and molecular inhibitors of the same. Particularly, GSTP1 (glutathione S-transferase P1) have been demonstrated as having a role in regulating the endothelial ISCU function in pulmonary hypertension. Accordingly, methods for treating pulmonary hypertension in a subject in need thereof comprising administering a therapeutically effective amount of a pharmaceutical composition that inhibits glutathione S-transferase P (GSTP1) and / or increasing ISCU expression are disclosed. The GSTP1 inhibitor can comprise a piperlongumine analog, such as BRD-K34222889, or a derivative thereof.

Compounds comprising sulfonyl-purine or sulfonyl-purine analog bonds are described for use as electrophiles in sulfonyl-purine (SuPUR) chemistry. Also described is the use of SuPUR and / or SuPUR chemistry for proteome labeling of reactive amino acid residues and for developing new covalent therapeutic agents that selectively modify select amino acid residues (e.g., tyrosine or lysine residues) in biologically active proteins and peptides, such as amyloid-beta (Aβ)-binding alcohol dehydrogenase (ABAD), guanine nucleotide binding protein alpha stimulating activity polypeptide (GNAS), alpha / beta-hydrolase domain 10 (ABHD10), glutathione S-transferase pi 1 (GSTP1), glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), poly(ADP-ribose) polymerase 2 (PARP2), and acetyl-CoA acetyltransferase 2 (ACAT2) proteins.

The present invention relates to the field of medicinal chemistry, specifically to a class of substituted benzenesulfonamide compounds and their applications. Pharmacological experiments have shown that the benzenesulfonamide compounds of the present invention have strong inhibitory activity against GSTP1-1 protein. Some compounds have anti-proliferative effects on tumor cells, including human lung cancer and cisplatin-resistant lung cancer, and have a certain degree of ability to reverse cisplatin resistance.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for reversing pancreatic cancer radiotherapy resistance by destroying redox balance and activating a ferroptosis procedure, and belongs to the technical field of medicine. Based on a new mechanism of pancreatic cancer radiotherapy resistance, i.e., tumor cells obtain resistance by up-regulating glutathione S-transferase P1 (GSTP1) to inhibit 5-lipoxygenase (ALOX5)-mediated ferroptosis, the invention provides a new application of a classic prescription dark plum pill or pharmaceutically acceptable extracts, effective parts or effective components thereof. According to the traditional Chinese medicine composition, by targeting a GSTP1 / ALOX5 axis, redox balance reconstructed in radiotherapy resistant cells is destroyed, lipid peroxidation and ferroptosis are reactivated, and therefore the sensitivity of tumor cells to radiotherapy is recovered. The radiotherapy sensitization effect and the mechanism of the dark plum pills are confirmed through systematic network pharmacology, bioinformatics analysis and in-vivo and in-vitro experiments, a brand new target spot and a treatment strategy are provided for overcoming pancreatic cancer radiotherapy resistance, and a scientific foundation is laid for modern development and clinical application of the dark plum pills.

The invention provides a method for rapidly and sensitively detecting GSTP1 (Glutathione S Transferase Protein 1) hypermethylated promoter DNA (Deoxyribose Nucleic Acid) of prostatic cancer in urine. Based on the liquid gate graphene transistor sensor, a bridge-shaped tetrahedral DNA probe is modified to the surface of a gold gate through a gold-sulfur bond, and a hypermethylated GSTP1 promoter converted by hydrosulphite can be selectively captured. Wherein DNA is treated by hydrosulfite, so that unmethylated cytosine (C) can be converted into uracil (U), and methylated cytosine (5-mC) is kept unchanged. According to the bridge-shaped tetrahedron DNA, due to the influence of electrostatic repulsion and space structure between two tetrahedrons, the transverse distance between curled ssDNA is easily controlled to improve the hybridization efficiency and reduce Debye shielding, the detection limit can be as low as 10-18 M, the wide linear detection range of 10 <-18 >-10 <-8 > M can be achieved, and the detection efficiency is greatly improved. The kit has a good detection effect in complex artificial urine and clinical practical sample detection, can effectively distinguish clinical urine samples of prostatic cancer patients and control groups, and has clinical application value.

The present application relates to the field of biotechnology, and application of a kuding tea and its extract and a product for preventing or treating hypertension. The product has the following effects: reducing the abundance of staphylococcus aureus (SA) in the intestinal tract or / and regulating the composition of the intestinal flora; reducing the level of at least one exotoxin secreted by SA in the body; up-regulating the expression of at least one of glutathione S-transferase and glutathione S-transferase P1 in the hypothalamic paraventricular nucleus. The present application also provides application of GSTM2 / GSTP1 as a target point in a product for preventing or treating hypertension. The present application is applied to a product for up-regulating the antioxidant defense (GSTM2 / GSTP1) of the hypothalamic paraventricular nucleus (PVN) through intestinal SA-exotoxin, and is further applied to prevention and treatment of hypertension. The present application provides a new target point for intervention in reducing blood pressure, and thus prepares a new product such as a drug for preventing and treating hypertension.